Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an allergy drug boost brain function in williams syndrome?

NCT ID NCT06087757

Disease control Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether clemastine, a common allergy medication, can improve thinking, motor skills, and social abilities in people with Williams syndrome. The study includes 30 participants aged 6 to 30 and uses a double-blind, placebo-controlled design to measure safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clemastine (an antihistamine allergy drug)
What this could lead to
If it works, this could point toward a treatment to improve thinking, movement, and social skills in people with Williams syndrome.
What could go wrong
This is a small, early-phase trial with only 30 people. The drug is being tested for a new purpose, so it may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals with Williams syndrome, which has been confirmed by genetic testing. * Ages 6-30. * Normal values in safety variables (e.g. Normal ECG 120-129/80-84). * No change in psychotropic medications and dosage during the last 4 weeks. * During the study, no pharmacological change that may impact the study (e.g. ADHD * medications). Exclusion Criteria: * Individuals with another genetic disorder besides Williams syndrome. * Individuals with Williams syndrome, younger than 6 or older than 30 years old. * Significant change in normal values in safety variables (e.g. high or low ECG). * Change in medications and dosage during the last 4 weeks prior the beginning and * during the study. * Pregnancy. * Using addictive substances such as alcohol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Williams syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Williams syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Williams syndrome

Contacts and locations

Locations

  • Child and Adolescent Psychiatry Unit, Sheba Medical Center

    Ramat Gan, Israel

  • Tel Aviv University

    Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.